{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:35:35Z","timestamp":1790634935940,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"am","delay-in-days":360,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013226","name":"Les Laboratories Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.dld.2022.09.015","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T04:43:23Z","timestamp":1666068203000},"page":"673-678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Immune checkpoint inhibitors for patients with isolated peritoneal carcinomatosis from dMMR\/MSI-H colorectal cancer, a BIG-RENAPE collaboration"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9360-2195","authenticated-orcid":false,"given":"Solenn","family":"Barraud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tougeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Villeneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarisse","family":"Eveno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Bayle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Parc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pocard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.dld.2022.09.015_bib0001","doi-asserted-by":"crossref","first-page":"743\u201152","DOI":"10.1097\/DCR.0000000000000412","article-title":"Epidemiology, management, and survival of peritoneal carcinomatosis from colorectal cancer: a population-based study","volume":"58","author":"Quere","year":"2015","journal-title":"Dis Colon Rectum."},{"issue":"5","key":"10.1016\/j.dld.2022.09.015_bib0002","doi-asserted-by":"crossref","first-page":"699\u2011705","DOI":"10.1002\/bjs.8679","article-title":"Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer","volume":"99","author":"Segelman","year":"2012","journal-title":"Br. J. Surg."},{"issue":"12","key":"10.1016\/j.dld.2022.09.015_bib0003","doi-asserted-by":"crossref","first-page":"1545\u201150","DOI":"10.1046\/j.1365-2168.2002.02274.x","article-title":"Peritoneal carcinomatosis from colorectal cancer","volume":"89","author":"Jayne","year":"2002","journal-title":"Br. J. Surg."},{"issue":"12","key":"10.1016\/j.dld.2022.09.015_bib0004","doi-asserted-by":"crossref","first-page":"1709\u201119","DOI":"10.1016\/S1470-2045(16)30500-9","article-title":"Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database","volume":"17","author":"Franko","year":"2016","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.dld.2022.09.015_bib0005","doi-asserted-by":"crossref","first-page":"256\u201166","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Qu\u00e9net","year":"2021","journal-title":"Lancet Oncol."},{"issue":"20","key":"10.1016\/j.dld.2022.09.015_bib0006","doi-asserted-by":"crossref","first-page":"5322\u201130","DOI":"10.1158\/1078-0432.CCR-14-0332","article-title":"Mismatch repair status and braf mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies","volume":"20","author":"Venderbosch","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.dld.2022.09.015_bib0007","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.3390\/cancers13123063","article-title":"Microsatellite Instability in Colorectal Cancers: carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies","volume":"13","author":"Randrian","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.dld.2022.09.015_bib0008","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx136","article-title":"The balance between cytotoxic t-cell lymphocytes and immune checkpoint expression in the prognosis of colon tumors","volume":"110","author":"Marisa","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"issue":"23","key":"10.1016\/j.dld.2022.09.015_bib0009","doi-asserted-by":"crossref","first-page":"2207\u201118","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"15_suppl","key":"10.1016\/j.dld.2022.09.015_bib0010","doi-asserted-by":"crossref","first-page":"3500\u20113500","DOI":"10.1200\/JCO.2021.39.15_suppl.3500","article-title":"Final overall survival for the phase III KN177 study: pembrolizumab versus chemotherapy in microsatellite instability-high\/mismatch repair deficient (MSI-H\/dMMR) metastatic colorectal cancer (mCRC)","volume":"39","author":"Andre","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.dld.2022.09.015_bib0011","doi-asserted-by":"crossref","first-page":"2509\u201120","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med."},{"issue":"9","key":"10.1016\/j.dld.2022.09.015_bib0012","doi-asserted-by":"crossref","first-page":"1182\u201191","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.dld.2022.09.015_bib0013","doi-asserted-by":"crossref","first-page":"659\u201170","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol."},{"issue":"20","key":"10.1016\/j.dld.2022.09.015_bib0014","doi-asserted-by":"crossref","first-page":"4623\u201132","DOI":"10.1002\/cncr.26086","article-title":"Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer","volume":"117","author":"Tran","year":"2011","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.dld.2022.09.015_bib0015","doi-asserted-by":"crossref","first-page":"285\u201196","DOI":"10.1002\/ijc.32879","article-title":"Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: an AGEO retrospective multicenter study","volume":"147","author":"Tougeron","year":"2020","journal-title":"Int. J. Cancer."},{"issue":"3","key":"10.1016\/j.dld.2022.09.015_bib0016","doi-asserted-by":"crossref","first-page":"254\u201161","DOI":"10.1002\/(SICI)1098-2388(199804\/05)14:3<254::AID-SSU10>3.0.CO;2-U","article-title":"Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis","volume":"14","author":"Sugarbaker","year":"1998","journal-title":"Semin Surg Oncol."},{"issue":"6","key":"10.1016\/j.dld.2022.09.015_bib0019","doi-asserted-by":"crossref","first-page":"481\u20117","DOI":"10.1634\/theoncologist.2019-0611","article-title":"Prediction of benefit from checkpoint inhibitors in mismatch repair deficient metastatic colorectal cancer: role of tumor infiltrating lymphocytes","volume":"25","author":"Loupakis","year":"2020","journal-title":"Oncologist"},{"issue":"6439","key":"10.1016\/j.dld.2022.09.015_bib0020","doi-asserted-by":"crossref","first-page":"485\u201191","DOI":"10.1126\/science.aau0447","article-title":"Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response","volume":"364","author":"Mandal","year":"2019","journal-title":"Science."},{"issue":"7","key":"10.1016\/j.dld.2022.09.015_bib0021","first-page":"1096\u2011103","article-title":"Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer","volume":"30","author":"Schrock","year":"2019","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.dld.2022.09.015_bib0022","article-title":"Pathological complete response to pembrolizumab in patients with metastatic ascending colon cancer with microsatellite instability","author":"Tominaga","year":"2021","journal-title":"Clin. J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.dld.2022.09.015_bib0023","first-page":"208\u201111","article-title":"Pathological tumor response following immune checkpoint blockade for deficient mismatch repair advanced colorectal cancer","volume":"113","author":"Ludford","year":"2021","journal-title":"J. Nat.l Cancer Inst."},{"key":"10.1016\/j.dld.2022.09.015_bib0024","article-title":"Prolonged treatment response to pembrolizumab in a patient with pretreated metastatic colon cancer and lynch syndrome","volume":"2019","author":"Keating","year":"2019","journal-title":"Case Rep. Oncol. Med."},{"issue":"2","key":"10.1016\/j.dld.2022.09.015_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004001","article-title":"Ascites and resistance to immune checkpoint inhibition in dMMR\/MSI-H metastatic colorectal and gastric cancers","volume":"10","author":"Fuc\u00e0","year":"2022","journal-title":"J. Immunother. Cancer."}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865822007265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865822007265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:22:33Z","timestamp":1761625353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865822007265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1590865822007265"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2022.09.015","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitors for patients with isolated peritoneal carcinomatosis from dMMR\/MSI-H colorectal cancer, a BIG-RENAPE collaboration","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2022.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}